Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.57 |
| ▸ | PREP | P48147 | 2/20 | 0.56 |
| ▸ | CCR1 | P32246 | 2/20 | 0.56 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.54 |
| ▸ | ELANE | P08246 | 4/20 | 0.54 |
| ▸ | CMA1 | P23946 | 4/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22209363 | 1.00 | ALDH1A1 (0.62) | ALDH1A1CYP3A4TSHRCAPN1CTSL | |
| SCHEMBL1506200 | 1.00 | ALDH1A1 (0.62) | ALDH1A1CYP3A4TSHRCAPN1CTSL | |
| SCHEMBL22209519 | 0.97 | ALDH1A1 (0.59) | ALDH1A1CYP3A4TSHRCAPN1CTSL | |
| SCHEMBL18620866 | 0.97 | ALDH1A1 (0.59) | ALDH1A1CYP3A4TSHRCAPN1CTSL | |
| SCHEMBL1992452 | 0.92 | FKBP1A (0.60) | ALDH1A1CYP3A4TSHRCAPN1CTSL | |
| SCHEMBL1506251 | 0.92 | ACE (0.61) | CAPN1CTSLCTSBCTSKPREP | |
| SCHEMBL10063674 | 0.92 | ACE (0.61) | CAPN1CTSLCTSBCTSKPREP | |
| SCHEMBL22209535 | 0.91 | CYP3A4 (0.60) | ALDH1A1CYP3A4TSHRCAPN1CTSL | |
| SCHEMBL18619599 | 0.91 | CYP3A4 (0.60) | ALDH1A1CYP3A4TSHRCAPN1CTSL | |
| SCHEMBL7285235 | 0.90 | CMA1 (0.60) | CAPN1CTSLCTSBCTSKPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257094-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-14 | — | — | US | disclosed |
| US-12312379-B2 | Methods for producing cyclic compounds comprising N-substituted amino acid residues | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-05-27 | — | — | US | disclosed |
| US-20220411462-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-12-29 | — | — | US | disclosed |
| WO-2022234864-A1 | METHOD FOR PRODUCING CYCLIC COMPOUND CONTAINING N-SUBSTITUTED AMINO ACID RESIDUE | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| EP-4086272-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411462-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | NGLY1, NPPA, VIP | ALDH1A1 4672/4885CYP3A4 2479/4885TSHR 3943/4885 |
| US-12312379-B2 | Methods for producing cyclic compounds comprising N-substituted amino acid residues | NGLY1, NPPA, VIP | ALDH1A1 4672/4885CYP3A4 2479/4885TSHR 3943/4885 |
| US-20250257094-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | NGLY1, NPPA, VIP | ALDH1A1 4672/4885CYP3A4 2479/4885TSHR 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.